Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed yesterday at $472.80.

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $503.00. The company’s shares ...

Deep-pocketed investors have adopted a bullish approach towards Vertex Pharmaceuticals VRTX, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Average portfolio weight of all funds dedicated to VRTX is 0.51%, an increase of 5.07%. Total shares owned by institutions increased in the last three months by 1.10% to 287,243K shares.

UBS has resumed coverage of Vertex Pharmaceuticals (NASDAQ:VRTX) with a buy rating, citing the company's growth potential. The investment bank said it believes Vertex (VRTX) has “best in sector ...

Good day. And welcome to the Vertex Pharmaceuticals Third Quarter 2024 Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there ...